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Abstract
Objectives: To test and further develop a healthcare policy and clinical decision support framework using growth
hormone (GH) for Turner syndrome (TS) as a complex case study.
Methods: The EVIDEM framework was further developed to complement the multicriteria decision analysis (MCDA)
Value Matrix, that includes 15 quantifiable components of decision clustered in four domains (quality of evidence,
disease, intervention and economics), with a qualitative tool including six ethical and health system-related
components of decision. An extensive review of the literature was performed to develop a health technology
assessment report (HTA) tailored to each component of decision, and content was validated by experts. A panel of
representative stakeholders then estimated the MCDA value of GH for TS in Canada by assigning weights and
scores to each MCDA component of decision and then considered the impact of non-quantifiable components of
decision.
Results: Applying the framework revealed significant data gaps and the importance of aligning research questions
with data needs to truly inform decision. Panelists estimated the value of GH for TS at 41% of maximum value on
the MCDA scale, with good agreement at the individual level (retest value 40%; ICC: 0.687) and large variation
across panelists. Main contributors to this panel specific value were “Improvement of efficacy”, “Disease severity”
and “Quality of evidence”. Ethical considerations on utility, efficiency and fairness as well as potential misuse of GH
had mixed effects on the perceived value of the treatment.
Conclusions: This framework is proposed as a pragmatic step beyond the current cost-effectiveness model,
combining HTA, MCDA, values and ethics. It supports systematic consideration of all components of decision and
available evidence for greater transparency. Further testing and validation is needed to build up MCDA approaches
combined with pragmatic HTA in healthcare decisionmaking.
Background
Healthcare decisionmaking is a complex process requir-
ing simultaneous consideration of a number of elements
including scientific judgment, economics and ethics.
The cost-effectiveness (CE) model has become a prime
model for healthcare resource allocation and decision-
making globally. It was developed to support decision-
making by integrating into unified metrics some of the
key elements considered to be important. Although the
methods developed in this field are valuable for examin-
ing the consequences of new healthcare interventions,
the focus on CE ratios (e.g. cost per quality-adjusted life
year [QALY]) has contributed to a “black box” syn-
drome, both at the clinical and policy levels[1,2] In addi-
tion, healthcare decisions need to be based on a wider
s e to fc o n s i d e r a t i o n st h a ta r en o tp a r to ft h eC Em o d e l
such as current need, lack of treatment and disease
severity [3-6].
A number of multicriteria models have emerged to
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ing [7-15]. Some elements of decisionmaking can be
quantified, and multicriteria decision analysis (MCDA)
provides a way to account for multiple streams of infor-
mation [16]. MCDA is emerging as a tool that goes
beyond cost-effectiveness by allowing integration of
more elements, such as disease severity [16-18]. In addi-
tion, MCDA provides a mechanism that allows decision-
makers to gain insight into their priorities and values
[19]. However, not all elements of decision are quantifi-
able (e.g., ethics, historical context) and may be difficult
to incorporate into an MCDA model. Culyer [20] sug-
gested a process that blends algorithmic (quantitative)
and deliberative (non-quantitative) approaches. Such a
comprehensive framework should allow explicit consid-
eration of all elements of d e c i s i o nb yaw i d er a n g eo f
stakeholders [21] to provide accountability for reason-
ableness [22].
Another critical point is how to inform decision-
makers on those elements of decision, the goal of health
technology assessment (HTA) activities–currently car-
ried out by governmental agencies, public and private
payers and manufactures around the world [5,23]. HTA
is as useful as the data available to build it, highlighting
the critical impact of clinical trial design, which is heav-
ily used to assess efficacy, safety, patient reported out-
comes and economic outcomes [4], and the transparent
reporting of results [1]. To fulfill their roles, HTA pro-
ducers should also inform socio-ethical dimensions of
new interventions [24]. However, although ethical eva-
luation helps stakeholders realize the consequences of
implementing a healthcare intervention at the micro
(patient), meso (institution) and macro (society) levels
[25], only 47% of the International Network of Agencies
for Heath Technology Assessment (INAHTA) member
organizations reported including ethics in their assess-
ments [26].
A decisionmaking framework bridging HTA with
MCDA was proposed [27] that provided a pragmatic
link between HTA and healthcare policy and clinical
decisionmaking. In a proof-of-concept study, the preli-
minary framework was applied to 10 drugs and tested
by 13 Canadian stakeholders during a panel session
(submitted manuscript). In the current study, a complex
case was tested to further explore the non-quantifiable
elements of decision, to develop a comprehensive frame-
work supporting consideration of all elements of deci-
sion, and to explore the validity of this approach. The
use of growth hormone (GH) to treat patients with
Turner syndrome (TS) was selected because of the com-
plexity of the considerations surrounding expensive hor-
mone injections over long periods of time to augment
height in growth-delayed children affected by this syn-
drome. It was also chosen because it is an approved
therapy and is used worldwide in developed countries
for Turner syndrome, a genetic condition affecting
between 1 in 2000 and 1 in 2500 live born females
[28,29].
Methods
Study design
The Evidence and Value: Impact on DEcisionMaking
(EVIDEM) framework includes a comprehensive set of
standard components of healthcare decision and a pro-
cess to consider each component, for which synthesized
data is made available in a matrix format. Components
that are quantifiable from a universal standpoint
(defined as intrinsic value components) are structured
into an MCDA matrix (the MCDA Value Matrix or
VM), which includes 15 components usually considered
in healthcare decisionmaking [27]. Other components of
decisions, which are not quantifiable from a universal
standpoint, i.e., related to the specific healthcare system
or ethical considerations (defined as extrinsic value
components [27]), were further explored, identified and
structured into a tool (Extrinsic Value Tool - see below).
A synthesized HTA report on growth hormone for
Turner syndrome tailored to each component of decision
was prepared and validated by experts (Figure 1).
A report on the quality of available evidence was gener-
ated using instruments for each type of evidence (Quality
Matrix). A panel of stakeholders estimated the intrinsic
value of growth hormone for Turner syndrome in
Canada by assigning weights and scores. The impact of
non-quantifiable (extrinsic) components of decision on
value was then evaluated. The validity of the approach
was explored by test-retest, discussion and survey.
Development of the Extrinsic Value Tool
Non-quantifiable components of decision such as ethical
and system-related considerations were identified based
on:
￿ extensive review of the literature and decision-
making processes;
￿ discussions with decisionmaking bodies and stake-
holders during workshops presenting the EVIDEM
framework; and
￿ discussions on extrinsic components of decision
during the proof-of-concept study with the 13 Cana-
dian panelists involved (policy decisionmakers, clini-
cians [specialists and general practitioners], nurses,
pharmacists, health economists/epidemiologists) who
evaluated 10 medicines using the EVIDEM frame-
work (submitted manuscript).
Six components were thus defined: three components
defining an ethical framework and three healthcare
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organized into a tool that asks evaluators whether each
component should be considered, and if so, would
impact positively or negatively on the value of the
intervention.
An ethical framework, combined with involvement of
all relevant stakeholders, are both critical elements in
the legitimization of healthcare decisions [30,31] and
they provide accountability for reasonableness
[22,32,33]. Although some ethical aspects are included
in the MCDA VM (e.g., the scale gives a higher value to
treatments that target severe disease compared to those
that target diseases that are not as severe), a more
complete ethical framework was integrated into the
Extrinsic Value Tool to make sure that additional ethical
principles are explicitly considered. Standard ethical
principles of a) utility, b) efficiency and c) fairness [34]
were combined with considerations of a) the goal of
healthcare, b) the opportunity costs, and c) the popula-
tion priorities and access to healthcare, respectively.
These three principles are often conflicting and the tool
allows identification of potential trade-offs.
Three system-related components were included in
the Extrinsic Value Tool, referring to non-scientific evi-
dence defined by Lomas [21]. System and organizational
capacity [8,21] and capacity to ensure appropriate use
Figure 1 Study plan.
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Page 3 of 15Table 1 HTA report with validated data for each component of decision of the framework (highly synthesized version)
Overview
Disease: Turner syndrome (TS)
Intervention: growth hormone
(GH)
Setting: Canada
Drug class: Polypeptide hormone
Indication: treatment of short stature in girls with Turner Syndrome
Administration: subcutaneous injection 3 to 7 days a week
Intervention duration: not established; initiate treatment as soon as growth failure demonstrated until
satisfactory height reached (in Canadian RCT, 6 years of treatment starting at 10 years)
Comparator(s): No treatment
Economic burden of illness: No data available
Intrinsic value components
(MCDA Value Matrix)
Highly synthesized information Scoring of intervention
Minimum score (0) Maximum
score (3)
Quality of evidence
Q1 Adherence to
requirements of
decisionmaking body
Not applicable for case study Low adherence High adherence
Q2 Completeness and
consistency of
reporting evidence
Epidemiology: limited statistical information; Clinical data:
limited reporting of AEs; PRO: incomplete reporting of
questionnaire dimensions; Economic evaluation: some model
features unclear; Budget impact: no sensitivity analysis reported
Many gaps/inconsistent Complete and
consistent
Q3 Relevance and validity
of evidence
Epidemiology: study in one Canadian hospital with small
sample size; Clinical data: uncertainty on final height gain, high
attrition rate in key RCT; PRO: interim analysis of a subset of
participants to a non blinded RCT; Economic evaluation:
questionable outcome -cost per cm of final height, no adverse
events costs, weak utility data; Budget impact: assuming all
Canadian girls treated based on prevalence data
Low relevance/validity High relevance/
validity
Disease impact
D1 Disease severity Female-specific genetic disorder characterized by short stature,
cardiovascular defects, absence of puberty, infertility, increased
risk of diabetes, defects in visuo-spatial organization and
nonverbal problem-solving, and decreased life expectancy
Not severe Very severe
D2 Size of population Prevalence: 40/100,000 female adults Very rare disease Common
disease
Intervention
I1 Clinical guidelines International guidelines (no Canadian guidelines): Consider GH
treatment as soon as growth failure is demonstrated and
potential risks/benefits have been discussed with patient/family.
Treat until satisfactory height is reached
No recommendation Strong
recommendation
I2 Comparative
interventions
limitations
There is no other therapeutic intervention indicated to treat
short stature in Turner syndrome
No or very minor
limitations
Major limitations
I3 Improvement of
efficacy/effectiveness
4 placebo controlled RCTs (2-year (toddlers) to 11-year
treatments; N = 42 to 104, 1 in Canada, 3 in USA): Final height
of treated patients = 147 cm to 150 cm (excluding toddlers);
difference with untreated = 7 cm
Observational controlled studies (2-year to 8-year treatments,
N = 26 to 123, 1 in Germany, 1 in Greece, 1 in Israel, 3 in Italy):
Final height of treated patients = 148 cm to 151 cm; difference
with controls = 2.1 to 6.8 cm
Lower than comparators Major
improvement
I4 Improvement of safety
& tolerability
Common AEs (from RCTs -frequency at least twice of
placebo): Surgeries (50%), ear problems (6% to 47%), joint
(13.5%) and respiratory (11%) disorders, sinusitis (18.9%)
Serious AEs (from registries, no control data): Intracranial
hypertension (0.2%), slipped capital femoral epiphysis (0.2 - 03.
%), scoliosis (0.7%), pancreatitis (0.1%), diabetes mellitus (0.2 to
0.3%), cardiac/aortic events (0.3%), malignancies (0.2%)
Warnings: Scoliosis, slipped capital femoral epiphysis,
intracranial hypertension, ear disorders, cardiovascular disorders,
autoimmune thyroid disease, insulin resistance
Lower than comparators Major
improvement
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version) (Continued)
I5 Improvement of
patient reported
outcomes
Inconclusive data:
1 RCT (2-year treatment data, N = 28, Canada): higher rating on
questionnaire by GH treated patients versus untreated for some
domains but not for others
2 observational studies: no significant differences on SF-36
dimensions in one study (5-year treatment, N = 568, France)
and significant differences in another (7-year treatment N = 29,
Holland); other questionnaires, non significant differences
Convenience: Subcutaneous injection 3 days a week or daily
Worse patient reported
outcomes than
comparators presented
Major
improvement
I6 Public health interest No data on risk reduction with GH treatment No risk reduction Major risk
reduction
I7 Type of medical
service
Goal of treatment: promote growth and improve psychosocial
wellbeing (height gain 7 cm, patient reported outcomes data
limited & inconclusive)
Minor service Major service
(e.g. cure)
Economics
E1 Budget impact on
health plan
Average annual cost of drug per patient: CAN$28,525
Annual impact for Canadian public drug plans: $11.3 million
(coverage for all 396 Canadian patients)
Substantial additional
expenditures
Substantial
savings
E2 Cost-effectiveness of
intervention
Incremental cost per additional centimeter in final height:
$23,630 (discounted at 5%);
Incremental cost per QALY gained $243,087 (discounted at
5%)
Not cost-effective Highly cost-
effective
E3 Impact on other
spending
Incremental cost per patient: $1,166 (includes training by
nurse, outpatient visits & X rays over 6 years - excludes drug
cost, see E1)
Substantial additional
spending
Substantial
savings
Extrinsic value components
(Extrinsic Value Tool)
Highly synthesized information Should this be considered? Would it impact
positively or negatively on value of
intervention?
Ethical framework*
Goals of healthcare -
utility*
Goal of healthcare is to maintain normal functioning which
may be impacted by very short stature. Goals of GH treatment
are to promote growth and improve psychosocial adaptation of
individual with short stature. However, psychosocial functioning
of individuals with short stature is largely indistinguishable from
their peers.
Opportunity costs-
efficiency*
Considering maximizing impact on health for a given level of
resources at:
Patient level: resources allocated to GH treatment may be more
beneficial if allocated to other interventions such as
psychological support to cope with condition overall (not just
short stature).
Society level: Significant cost/person but small population.
Population priority &
access - fairness*
Prioritize worst off: applicable to patients with Turner
Syndrome but maybe not to the short stature part of the
disease; daily lot probably not improved with daily injections for
several years, but maybe as adult with less short stature than
without treatment.
Treat like cases similarly: should we treat differently short
stature due to disease or due to genes?
Access to care/treatment: easier in big cities where specialists
are available
Other components
System capacity and
appropriate use of
intervention
Optimal age for initiation of treatment has not been
established. Appropriate follow up requires the intervention of
skilled healthcare professionals
In Canada, any physician can prescribed GH; some of the
provinces that reimburse GH require it is prescribed by an
endocrinologist.
Stakeholder pressures Pressure from parents, from clinicians, industry?
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groups is often part of the whole mechanism leading to
healthcare decisions [21] and should be made explicit to
ensure that all interests at stake are known by the deci-
sionmakers [35]. This also includes the interest of the
decisionmakers themselves [26]. Political priorities and
historical context, including habits, traditions, and pre-
cedence [21,36], may also affect the value of the inter-
vention under scrutiny.
Although these six components are not quantifiable
from a universal viewpoint and are thus considered qua-
litatively in the framework, some may become so in spe-
cific settings, providing that there is agreement on the
low and high ends of the scale and that data can be
gathered to operationalize them.
Health technology assessment report
Synthesized evidence about growth hormone treatment
for patients with Turner syndrome in Canada was pre-
pared following the EVIDEM methodology [27]. An
extensive analysis of the literature was performed to
identify most relevant available data (i.e., data obtained in
Canadian population, with comparative data for no treat-
ment/placebo) supplemented by key studies in other set-
tings. Databases and sources searched included PubMed,
Centers for Review and Dissemination, Cochrane, trial
registries, Disease Association web sites (Canadian
Turner syndrome society; Turner Syndrome Society of
United States; Eunice Kennedy Shriver National Institute
of Child Health and Human Development, American
Academy of Pediatrics; and Turner Syndrome society in
France, UK, and Australia), websites of the Agency for
Healthcare Research and Quality (AHRQ), the National
Institute for Clinical Excellence (NICE), the Canadian
Agency for Drugs and Technologies in Health (CADTH),
and the World Health Organization (WHO), completed
by hand searching of bibliographies. Search terms
included: Turner syndrome, growth hormone/GH/rhGH/
somatropin, quality of life/QoL/HRQoL, epidemiol*/pre-
valence/incidence, mortality, guideline/recommendation/
clinical practice, patient reported outcome*/PRO, cost*,
econom*, productivity, ethic*.
For clinical evidence, randomized controlled trials
with complete comparative data on final or adult height
(considered most important primary outcome [37]) were
included. Although it did not report adult height, a
randomized controlled clinical trial with 2-year old
patients was also included to inform potential changes
in clinical practice in treating very young patients. Sum-
mary data from observational studies was included if
they reported final height, based on the assertion that
considering both types of evidence better informs deci-
sionmaking [38]. Safety data was obtained from regis-
tries, clinical trials and product monographs. Patient
reported outcomes (PRO), epidemiological and eco-
nomic data in Canada was supplemented by data from
other countries. Canadian clinical guidelines were not
available and guidelines from US were used. Data thus
selected was synthesized for each component of the
MCDA VM to inform scoring.
T h eq u a l i t yo fe v i d e n c ef o u n dw a sa s s e s s e du s i n gt h e
Quality Matrix (QM) instruments [27] for five types of
evidence (clinical, patient reported outcomes, epidemio-
logical, economic and budget impact analysis) and for
two criteria of quality ("completeness and consistency of
reporting” and “relevance and validity of evidence”). For
each type of evidence, studies most relevant to the
Canadian setting were assessed. Due to the subjective
nature of these types of assessments [39], transparent
reporting of a critical analysis of each study was com-
bined with a three-step process to reach a consensus.
First, a trained investigator reviewed the study, provided
comments for each dimension of the QM instruments, a
score and the rationale for that score for each study
(or group of studies, e.g., clinical trials). All evaluations
were then reviewed by a second trained investigator and
validated by an expert in the field (Figure 1).
To explore the extrinsic value of growth hormone for
patients with Turner syndrome, a review of the litera-
ture on the ethical, psychosocial and contextual aspects
of growth hormone treatment was performed. Concepts
and information were categorized and synthesized using
the Extrinsic Value Tool.
The HTA report thus generated was programmed into
an interactive web based prototype using Tikiwiki v2.2
The prototype allowed experts performing validation to
access the HTA report online as well as full text source
documents, and to enter feedback on the synthesized
data, critical analysis of evidence, and quality scores.
Clinical, PRO, and epidemiological data was validated by
a clinician with extensive expertise in Turner syndrome.
Economic data was validated by a health economist.
Table 1: HTA report with validated data for each component of decision of the framework (highly synthesized
version) (Continued)
Political/historical
context
Societal pressure on short stature?
Other components?
*Ethical framework based on three principles; when conflicting principles, clearly identify trade-offs and legitimate decision by engaging a broad range of
stakeholders & explaining decision; legitimizing decision is key to provide accountability for reasonableness
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The panel was designed to include relevant stakeholders,
with a focus on experts in the disease to explore rela-
tionships between policy and clinical decisionmaking.
Stakeholders were contacted by email with an invitation
letter describing the project, were offered identical mini-
mal honoraria, and their expenses were covered. The
panel was composed of:
◦ 4 academic pediatric endocrinologists with exten-
sive clinical experience with trial design and with
patients with Turner syndrome
◦ 1 ethicist who was also a pediatrician
endocrinologist
◦ 1 nurse with extensive clinical experience with
Turner syndrome
◦ 1 Turner syndrome patient/patient group
representative
◦ 2 health economists/epidemiologists who had
exposure in health policy decisionmaking.
Value of growth hormone for Turner syndrome
The web-based prototype was used by the nine panelists
to read the HTA report prior to the panel session. Each
panelist then applied the framework during the panel
session (test) to assess the value of growth hormone for
patients with Turner syndrome. This was repeated
online at least two weeks after the panel session (re-test)
(Figure 1). Intrinsic value was assessed using the MCDA
VM (steps 1 and 2) and extrinsic value using the Extrin-
sic Value Tool (step 3).
◦ Intrinsic value (estimated by combining weights
and scores):
◦ Step 1: Weighting of MCDA intrinsic value
components independently of intervention and
from a societal perspective; a scale of 1 to 5 was
used.
◦ Step 2: Scoring of MCDA intrinsic value com-
ponents for the intervention using the synthe-
sized data reported in the MCDA VM and a
scoring scale of 0 to 3 with defined anchors
and scoring examples; the MCDA VM included
features to collect feedback on the synthesized
data and the evaluating process, and to
specify whether a low score was due to data
limitations.
◦ Extrinsic value
◦ Step 3: Considering extrinsic value components
and their impact on the value of growth hor-
mone for patients with Turner syndrome using
synthesized data.
Feedback was also collected during a discussion period
during the day of the panel and from a questionnaire
administered after the panel session.
Data collection and statistical analyses
For the panel evaluation (test), weights, scores and con-
sideration of extrinsic components were obtained on the
hardcopy documents distributed to panelists and
entered in Excel software. Data entered on-line by pane-
lists (retest) was recorded in a MySQL database and
transferred to the Excel software, which was then used
to perform statistical analyses.
The estimated intrinsic value of growth hormone for
Turner syndrome was obtained by applying an MCDA
linear additive model combining normalized weights
and scores for all components of the MCDA VM [27].
Mean, standard deviation (SD), minimum and maximum
values were calculated. MCDA value estimates from one
evaluator differed by more than 50% between test (2.0
or 75%) and retest (1.15 or 38%), indicating systematic
error, and was excluded from statistical analyses.
Agreement between test and retest data was analyzed
by calculating intra-rater correlation coefficients (ICCs)
for weights, scores and MCDA value estimates. Two
types of ICCs were calculated following Shrout and
Fleiss (1979) [40] methods and classification: the ICC
(3,1) which is based on a two-way mixed analysis of var-
iance (ANOVA) model (general effects of the test and
the retest were assumed to be fixed); and the ICC (1,1),
which is based on a one-way ANOVA model and
assumes that test and retest data do not differ in a sys-
tematic way and are therefore interchangeable. In addi-
tion, the proportion of data pairs that did not differ
between test and retest, differed by 1 point, and by 2
points, was calculated for weights and scores.
Inter-rater correlation coefficients were not calculated
since the tool is designed to capture personal values and
perspectives, which are expected to vary across
individuals.
Results
Health technology assessment report
The HTA report summarized current knowledge on
growth hormone for patients with Turner syndrome
within the Canadian context and was validated by
experts. Data was organized to directly feed into the
MCDA VM and the Extrinsic Value Tool to provide, in
a practical manner, the data that is necessary to con-
sider each element of decision. A highly synthesized ver-
sion of the data presented to panelists is reported in
Table 1 (details, referencing, and access to sources are
available on the collaborative registry at http://www.evi-
dem.org/evidem-collaborative.php). Because there is no
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stature in Turner syndrome, no treatment was used as
the standard comparative treatment option.
Growth hormone is the only available intervention
indicated for the treatment of short stature in girls with
Turner syndrome, a rare (1 in 2000) genetic disorder
characterized by reduced life expectancy, absence of
puberty, cardiovascular defects and short stature (about
20 cm lower that mean adult height of North American
women). Treatment requires daily injections over several
years but optimal duration of treatment and age of
initiation have not been established. Compared to no
treatment, randomized controlled trials and observa-
tional studies report an average height gain of 7 cm, and
2 to 7 cm, respectively, for a final height of about
150 cm. Growth hormone carries many warnings and its
safety profile in Turner syndrome patients is character-
ized by increases in middle ear problems & related sur-
geries (vs no treatment, randomized controlled trial) as
well as very rare but serious adverse events reported in
registries. The impact it has on the patient quality of life
is inconclusive with limited data. Thus beyond increas-
ing height, it is unknown whether growth hormone pro-
vides long-term quality of life benefits, a problem
common to HTA of many drug therapies. The annual
drug cost per patient is about CAN$29,000, with other
costs estimated at about $1,200 per year. The annual
budget impact on drug plans in Canada is estimated to
be $11.3 million and its cost per QALY ranges from
$56,000 (not discounted) to $243,000 (discounted).
Other aspects of the decision were identified and-
reported in the Extrinsic Value Tool including the
(mis)alignment of growth hormone with the goal of
healthcare to maintain normal functioning, optimal allo-
cation of resources at patient and society level, fairness
in treating short stature, potential inappropriate use
given limited guidelines on optimal treatment and
p o t e n t i a lc u l t u r a la n ds t a k e h o l d e rp r e s s u r e so ns h o r t
stature.
Value of growth hormone for Turner syndrome
The mean intrinsic MCDA value estimate of growth
hormone for patients with Turner syndrome was 1.23
(41% of maximum value), ranging from 0.79 (26%) to
1.61 (54%) among panelists (Figure 2). This was
obtained by a linear combination of normalized weights
and scores, for which large variations between panelists
were observed (Figure 3). The intrinsic MCDA estimate
was a reflection of:
1- Personal values & perspective (weights) of pane-
lists regarding the relative importance of each com-
ponent of decision; at the panel level, “Improvement
of efficacy” was identified as the most important
component (4.8 ± 0.5), and “Size of population” and
“Clinical guidelines” as the least important (3.1 ± 1.1
and 3.1 ± 1.4, respectively; Figure 3)
2- Comprehensive performance (scores) of the inter-
vention for a range of quantifiable components
(Figure 3)
Contribution of the cluster of components categorized
as “Intervention” to the MCDA estimate was the most
important (50%), while the “Economics” cluster contrib-
uted least (11%) (Figure 3). At the component level, the
main contributors were “Improvement of efficacy
(I3; 14% of total value)”, followed by disease severity
(D1; 11%), quality of evidence (Q2 and Q3; 11% & 10%)
and limitations of comparative interventions (10%)
(Figure 3).
This MCDA value estimate laid the groundwork
for ethical and healthcare system related considerations
(Table 2). The impact of these on the value of the inter-
vention was mixed and sometimes conflicting, highlight-
ing the importance of explicitly considering such
components as part of the entire process of
decisionmaking.
In reviewing the synthesized data of the MCDA VM, a
discussion was sparked about what comprises a mean-
ingful outcome for the patient (what is the value of a
statistical difference of 7 cm?), highlighting the impor-
tance of the original research question. Limited data on
quality of life benefits and failure to compare growth
hormone treatment with psychosocial support or other
strategies for wellbeing was also noted, as was absence
of long term comparative data for a treatment with a
lifetime impact. Cost-effectiveness data–especially wide
variation between discounted and undiscounted data
results–caused frustration among panelists regarding the
real significance of these metrics, especially since dis-
counting disadvantages children, which was seen as
inequitable. Beyond its impact on drug costs, there was
little short term data regarding the economic impact of
growth hormone on other healthcare resources, and
complete absence of long-term data, all of which
severely limited interpretation and assessment of com-
ponent E3 (Impact on other spending).
Exploratory validation of approach
When surveyed whether each component of decision of
the framework (Intrinsic and Extrinsic Value Compo-
nents) should be considered in the decisionmaking pro-
cess, panelists indicated that they would consider most
of them except for “Stakeholders pressures” (33% of
panelists would not consider this component), “Clinical
guidelines” (25%), “Adherence to requirements of deci-
sionmaking body” (13%) and “Type of medical service”
(11%).
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Page 8 of 15Figure 2 Intrinsic value estimate for intervention on the MCDA Value Matrix scale and value contribution of each component. *For an
intervention to achieve close to 100% on this scale, it would have to cure a severe endemic disease, demonstrate a major improvement in
safety, efficacy and PRO compared to limited existing approaches, and result in major healthcare savings. Conversely, an intervention that scores
low would be for a rare disease that is not severe, with minimal improvement in efficacy over existing alternatives, with major safety and PRO
issues and resulting in major increases in healthcare spending.
Figure 3 Weights for MCDA Value Matrix components and scores for growth hormone for Turner syndrome in Canada (average data
from eight panelists). *A five point weighting scale was used with 1 lowest and 5 highest weight. **A short four point scoring scale was used
with 0 lowest (to account for component that would not bring any value) and 3 highest score.
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Page 9 of 15Table 2 Extrinsic value tool: component definitions and panelists’ considerations on the value of growth hormone for
Turner syndrome
Extrinsic value
components
Definition Panelists’ considerations
Ethical framework*
Goals of
healthcare -
utility*
Goal of healthcare is to maintain normal functioning. Such
consideration is aligned with the principle of utility, which
considers the act to produce the greatest good or “greatest
benefits for the greatest number”
Considered: Panelists reported that the goal of healthcare
(i.e., addressing medical issues rather than social issues)
should be considered, and that height is not entirely a social
issue, but also a medical issue for very short patients.
Impact: Therefore for very small patients, there is a medical
utility in facilitating normal functioning (reaching car pedals,
kitchen cabinets etc), which would impact positively on the
intrinsic value of the intervention.
On the other hand, weak evidence linking improvement in
minor short stature with personal gain would have a
negative impact on value.
Opportunity costs-
efficiency*
Opportunity costs include resources or existing interventions
that may be forgone if intervention under scrutiny is used/
reimbursed. Such consideration is aligned with the principle
of efficiency, which considers maximizing impact on health
for a given level of resources (efficiency can be considered
at the patient level and at the society level)
Considered: Panelists indicated that this should be
considered to capture the opinions of stakeholders
Impact: would have a negative impact on value, more value
might be derived from psychosocial support.
Comment: Resources are often allocated to measurable
outcomes (e.g., height) rather than softer outcomes such as
psychosocial benefits.
Population priority
& access -
fairness*
Priorities for specific groups of patients are defined by
societies/decisionmakers and reflect their moral values. Such
considerations are aligned with the principle of fairness,
which considers treating like cases alike and different cases
differently and often gives priority to those who are worst-
off (theory of justice)
Considered: Panelists indicated that this should be
considered
Impact: mixed impact - negative impact related to the
concept of treating like cases similarly (e.g., short stature due
to other diseases) as it dilutes the importance of TS patients
relative to other groups
Comment: should not discriminate against rare diseases;
there should be public debate on priorities
Other components
System capacity
and appropriate
use of
intervention
The capacity of healthcare system to implement the
intervention and to ensure its appropriate use depends on
its infrastructure, organization, skills, legislation, barriers and
risks of inappropriate use. Such considerations include
mapping current systems and estimating whether the use of
the intervention under scrutiny requires additional capacities
(note: if available, economic estimate would be included in
the economic component E3 of the MCDA Value Matrix)
Considered: some panelists indicated that it should be
considered while others indicated there was no potential for
inappropriate use
Impact: for those who indicated it should be considered, it
would have a negative impact on value
Comment: although there is no risk of misdiagnosis (genetic
testing), because guidelines are not clear on age initiation,
there is a risk of having all toddlers initiated on treatment,
which was considered as inappropriate use.
Misuse of growth hormone is possible (gaining height for no
medical reason) and there are no mechanisms in place for
surveillance of inappropriate use.
Stakeholder
pressures
Pressures from groups of stakeholders are often part of the
context surrounding healthcare interventions. Such
considerations include being aware of pressures and
interests at stake and how they may affect values of
decisionmakers
Considered: some panelists indicated that it should be
considered while others reported that it should not be taken
into account
Impact: for those who indicated it should be considered, it
would have a negative impact on value.
Comment: Lobby groups are effective at reaching and
impacting decisionmakers
Political/historical
context
Political/historical context may influence the value of an
intervention in consideration of specific political situations
and priorities as well as habits, traditions and precedence
Considered: Panelists indicated that this should be
considered
Impact: none reported
Comment: This includes the political will to demonstrate
fairness to rare disorders as well as universal access to care
(guaranteed by the Canadian healthcare system) to satisfy
entitlement felt by affected families.
Budgetary context (i.e., recession, balanced budget or
surplus) affects decisions.
Other
components
Components that are not already captured in the standard
set proposed
*Ethical framework based on three principles; when conflicting principles, clearly identify trade-offs and legitimize decision by engaging a broadr a n g eo f
stakeholders & explaining decision; legitimizing decision is key to provide accountability for reasonableness
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Page 10 of 15Applying the MCDA VM during the panel (test)a n d
then re-applying it individually on-line (retest) yielded
mean MCDA value estimates of 1.23 for the test and
1.20 for the retest (Table 3). The ICC (3,1) was 0.656
and the ICC (1,1) 0.687 indicating fair to good reprodu-
cibility. When the data from the outlier was included,
ICC (1,1) dropped to 0.367 and ICC (3,1) to 0.371. Data
below is excluding the outlier.
Weights tended to show lower test-retest agreement
than scores, with ICC (3,1) of 0.578 and 0.681 for
weights and scores, respectively, indicating that they
were to a larger degree responsible for test-retest dis-
agreements in MCDA value estimates than changes in
scores.
A p p r o x i m a t e l yh a l fo ft h e1 2 0w e i g h t s( 5 0 . 8 % )w e r e
identical between test and retest, 39.2% differed by
1 point (on a scale of 1 to 5), and 10.0% differed by
2 points. Cluster D (comprised of components Disease
severity and Size of population affected by the disease)
recorded the greatest disagreement between test and
retest weights (only 37.5% were identical) of the four
clusters of the VM (i.e., Q: Quality of data, D: disease
description, I: intervention characteristics, E:
economics).
With respect to test-retest comparison of scores,
65.2% were identical, 28.6% differed by 1 point (on a
scale of 0 to 3), and 6.3% differed by 2 points. Cluster
E (comprised of the 3 components Budget impact on
health plan, Cost-effectiveness of intervention,a n d
Impact on other spending) recorded the greatest varia-
tion in scores between test and retest (58.3% of scores
were identical; 12.5% differed by 2 points) of the four
clusters. The components Cost-effectiveness of interven-
tion and Impact on other spending, both based on cost-
effectiveness analysis, were largely responsible for the
greater disagreement in scores for Cluster E, while
scores for the component Budget impact on health plan
showed little disagreement between test and retest.
Discussion
The current debate on transparency and legitimacy of
healthcare decisionmaking [41,42] calls for a more sys-
tematized approach to evidence review and decision-
making. In particular, ethical and colloquial (e.g., not
based on scientific evidence) considerations are inherent
to the thought process underlying healthcare decision-
making [21,43] but are often not explicitly acknowl-
edged or discussed, let alone communicated to other
stakeholders. The EVIDEM framework proposes a com-
prehensive set of components of decision to consider in
making healthcare choices, and transparent access to
available data on which these considerations are based.
This approach is envisioned to help identify the issues
at play and increase legitimacy and transparency of
decisions.
Testing the EVIDEM framework using the complex
case of growth hormone for patients with Turner syn-
drome allowed development of a complementary tool
(Extrinsic Value Tool), thus expanding the comprehen-
sive nature of the framework. Applying the framework
to this case clearly exposed limitations of the cost-effec-
tiveness paradigm and highlighted the importance of
systematically considering all relevant aspects of an
intervention to best reach an informed decision. It also
revealed gaps in available data and a need to better align
research questions with data needs. Exploratory valida-
tion of the approach provided support for the inclusion
of most framework components and showed good
agreement of MCDA value estimates at the individual
level (test-retest) but large variations across panelists
reflecting different perspectives and personal values.
This case study exemplifies how MCDA can provide a
means to integrate a wider range of components into
the decisionmaking process [16] and help consider each
of them explicitly. The use of growth hormone is com-
plex and raises many questions, including far reaching
issues such as social perception of short stature (What
Table 3 Agreement at the individual level between test-retest for weights, scores and MCDA estimates obtained with
the MCDA Value Matrix
Weights Scores MCDA Estimates
Number of test-retest pairs 120* 112
† 8
Mean of test data 4.03 1.33 1.23
Mean of retest data 3.74 1.28 1.20
ICC (3,1) 0.578 0.681 0.656
ICC (1,1) 0.546 0.682 0.687
Proportion of pairs with no test-retest difference (%) 50.8 65.2 NA
Proportion of pairs with test-retest difference of 1 point (%) 39.2 28.6 NA
Proportion of pairs with test-retest difference of 2 points (%) 10.0 6.3 NA
*8 evaluators × 15 components;
†8 evaluators × 14 components (component Q1 was not scored for case study)
NA: Not applicable
ICC: intra-class correlation coefficient, defined according to Shrout and Fleiss (1979) [40]
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Page 11 of 15is short stature? Why is it an issue? What is the value of
an incremental gain in stature?) In addition, considera-
tion of the ethical components of the Extrinsic Value
Tool brought up questions of fairness towards Turner
syndrome patients versus other individuals with short
stature [33,44]. Decisionmaking that solely relies on the
cost per QALY ignores these issues, leaving them at
best to ad hoc discussions. The clear inadequacy of
the available utility data and the great difference
between discounted and non-discounted incremental
cost-effectiveness ratios (because high costs are incurred
during childhood, but benefits accumulate over adult
life-time) observed for this case study cast additional
doubt upon reliance on the cost per QALY measure and
highlight the usefulness of a more comprehensive
approach.
In a first step, applying the framework allows eliciting
the personal values of the committee/panel members
(weighting). Variations across individuals are expected
and were observed in the case study reflecting different
perspectives and potential bias. Of note, panelist weights
were lowest for “Clinical guidelines”, suggesting limited
impact of these, perhaps related to the current debate
surrounding guideline limitations [45].
In a second step, combining panelist weights and
scores for the intervention, produces an MCDA value
estimate–a panel-specific comprehensive measure inte-
grating relative value (i.e., comparative efficacy, safety,
patient reported outcomes, impact on treatment budget
and other spending, cost-effectiveness), absolute value
(i.e., severity of disease, size of population affected, types
of benefit at population and patient level, quality of evi-
dence), as well as clinical guidelines and the limitations
of alternative interventions. In this case study, the
MCDA estimate was 41% of maximum value, with
major drivers including “Improvement of efficacy” (14%
of total MCDA estimate), “Disease severity” (11%) and
“Quality of evidence” (22%, for Q2 and Q3 combined).
Although not directly comparable due to different panel
compositions, this MCDA estimate is at the lower range
(42% - 64%) of estimates obtained during the proof-of-
concept study for 10 medicines approved in Canada
(submitted manuscript). Further research is needed to
position MCDA estimates within a frame of reference.
T h ep r o c e s so fc o n s i d e r i n gt h eq u a n t i f i a b l ec o m p o -
nents of decision lays the groundwork for the third step
in which qualitative ethical and healthcare system
related factors are being considered. The MCDA esti-
mate is not intended to be used in a formulaic approach
[16], but rather as an attempt to tease out all relevant
quantifiable components and to then consider the
impact of other ethical and contextual elements influen-
cing overall value. In this case study, issues identified
included the medical utility of height gain (Utility),
provision of psychosocial support as an alternative (Effi-
ciency), policy towards rare diseases with respect to dis-
crimination and priority setting (Fairness, Political
context) and potential misuse in toddlers (System capa-
city/appropriate use). Although these issues had mixed
effects on the perceived value of the intervention under
scrutiny, panelists noted that the process helps ensure
awareness of all historical, political, system-related and
ethical elements that may impact the decision. Overall,
the framework encouraged a better analysis of the issues
that troubled panelists subconsciously, rendering them
more explicit in this assessment.
Exploring the validity of the framework revealed that
panelists would consider most of its components to
assess a healthcare intervention, thus providing some
support for the current set of components. Although
validation in terms of agreement across panelists was
not possible since the tool is designed to capture differ-
ences of personal values, exploration of intra-rater
agreement between weights and scores obtained during
test and retest revealed a fair to good agreement at the
individual level (ICC = 0.6). Weights were, to a larger
degree than scores, responsible for test-retest disagree-
ment in value estimates, suggesting that panelists were
still wrestling with their own values, or interpreted the
components of the MCDA VM differently. Alternatively,
this may have arisen because the panel was not yet com-
fortable enough with the process; this latter hypothesis
is testable by examining individual test-retest data over
time. For weights, largest variations were observed for
disease-related components suggesting some difficulty in
deciding on the importance of disease severity (D1) and
size of population (D2). It may also reflect difficulty in
positioning Turner syndrome on a scale encompassing
all diseases, since specialists typically focus on their
practice and tend to rank diseases and interventions
within the range of patients they see [25]. For scores,
the largest degree of test-retest disagreement at the indi-
vidual level was observed for cost-effectiveness-based
components, highlighting the difficulties in making
sense of CE ratios and frustration associated with the
systematic negative effect of discounting on cost/QALY
ratios for interventions for children. Although CE ratios
were included in the framework to make a connection
with the current predominant model, this may not be
necessary and separately considering definite expendi-
tures (e.g., drugs costs - E1) and potential savings (e.g.,
hospital stay - E3) may be more informative and better
aligned with the natural thought process underlying
decisionmaking.
Discussing amongst a range of stakeholders all the
components of decisionmaking on the basis of a struc-
tured HTA report that presents the available evidence
(in its broad sense, i.e., both scientific and colloquial)
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lists as a useful means of revealing data gaps and identi-
fying research questions. This can lead to improved
study design and hopefully ensure better alignment of
data generation with data needs at the micro, meso and
macro levels. In this case, the process revealed the need
for defining truly relevant outcome measures. From the
patient perspective, height increase was seen as useful if
it could permit normal functioning by bringing the
patient from very small to small, highlighting the impor-
tance of patient involvement in sound decisionmaking
[46-48]. Comparative data concerning alternative strate-
gies to improve adaptation of individuals with short sta-
ture (e.g., psychological support) was also limited, but
seen as important to assess the value of growth hor-
mone, in line with previous studies [49,50].
Limitations
Results of this case study should be considered in light
of limitations. As stated in the introduction, any HTA is
only as useful as the data available to build it, but it is
also dependent on the care taken in collecting and
extracting all appropriate data for analysis. While this is
a laborious process, it is hoped that the availability of an
open-source data repository will lead to time savings,
since the same data is currently gathered independently
by many individuals generating HTA. Integrating both
t h ed a t aa n dt h ef r a m e w o r ki no n ep a n e ls e s s i o nw a s
challenging for some panelists. Although the panelists
involved in the proof-of-concept study (submitted
manuscript), who each evaluated several interventions
using the MCDA VM, felt that the process became fairly
clear after a couple of applications, a simplified version
of data provided was developed for further testing (a
‘lite’ version).
Although variations across panelists in weights and, to
a lesser extent, in scores are expected due to diverse
perspectives and values, they may also be due to differ-
ent data interpretation or misunderstanding (of data or
of process), highlighting the importance of good coordi-
nation and communication to integrate the deliberative
process [20] where there are several thought processes
and perspectives at play (which can be captured at the
individual level with the framework). Value assessments
and considerations are those of a small group of stake-
holders, which is often the ca s ei nt h ep o l i c yd e c i s i o n -
making process.
We used a direct method for weight elicitation, which
may not capture implicit or unconscious thoughts or
preferences [51]. However, one of the objectives of the
EVIDEM framework is to raise awareness of the compo-
nents underlying decisionmaking. It is our hope that
such process will make streams of thought more explicit
and easier to communicate among stakeholders. Finally,
this study was not designed to directly compare EVI-
DEM to other approaches used by decisionmaking
bodies, such as cost-utility thresholds, and field studies
comparing the EVIDEM approach to current decision-
making processes are being developed.
Conclusion
The EVIDEM framework is proposed as a step beyond
the current cost-effectiveness model, combining efficient
HTA, pragmatic MCDA, and an ethical framework to
ensure systematic consideration of all components of
decisionmaking and evidence available, and to provide a
transparent record of how these elements have been
used to reach a decision. It constitutes a concrete step
towards addressing some of the elements identified as
key to successful decisionmaking [42] and for account-
ability for reasonableness [22]. Systematically consider-
ing all pieces of the puzzle for healthcare interventions
by all stakeholders leads to difficult questions, helps to
position interventions across a wide range of options,
including preventive and curative programs as advocated
by Nord [3], and may enhance social responsibility and
reduce bias.
The framework is primarily designed to stimulate and
make more explicit the natural thinking process under-
lying decisionmaking and deliberation. Although deci-
sionmaking contexts are diverse, we propose that the
same comprehensive set of components can be consid-
ered in a broad range of circumstances because they can
be easily adapted to user needs at both policy and clini-
cal levels. HTA reports organized in the format of this
framework to inform components deemed necessary can
be used to stimulate reflection and deliberation. MCDA
estimates can also be used to establish a ranking system
that can encompass a broad range of healthcare inter-
ventions and is consistent with user priorities and
values. The framework is applicable to decisions on
healthcare interventions for which there are many com-
parators since it provides a pragmatic reporting of com-
parative effectiveness; this is currently being tested for
pain management. The framework is also applicable for
research planning, communication and knowledge trans-
lation; the last is currently being explored through a
web-based open-access collaborative registry structuring
data on healthcare interventions (high level synthesis,
details and full text sources) using the framework com-
ponents of decision. Further testing and validation is
needed to build up MCDA approaches combined with
pragmatic HTA in healthcare decisionmaking.
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